A detailed history of Herold Advisors, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Herold Advisors, Inc. holds 2,250 shares of BNTX stock, worth $254,542. This represents 0.06% of its overall portfolio holdings.

Number of Shares
2,250
Holding current value
$254,542
% of portfolio
0.06%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$78.36 - $124.66 $176,310 - $280,485
2,250 New
2,250 $267,000
Q1 2024

May 10, 2024

BUY
$88.96 - $112.35 $13,343 - $16,852
150 Added 7.32%
2,200 $202,000
Q4 2023

Feb 02, 2024

BUY
$90.91 - $112.75 $4,545 - $5,637
50 Added 2.5%
2,050 $216,000
Q3 2023

Nov 08, 2023

SELL
$98.5 - $125.08 $98,500 - $125,080
-1,000 Reduced 33.33%
2,000 $217,000
Q1 2022

May 09, 2022

BUY
$126.25 - $231.85 $126,250 - $231,850
1,000 Added 50.0%
3,000 $511,000
Q3 2021

Nov 03, 2021

BUY
$205.93 - $447.23 $411,860 - $894,460
2,000 New
2,000 $545,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.5B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Herold Advisors, Inc. Portfolio

Follow Herold Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Herold Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Herold Advisors, Inc. with notifications on news.